CervoMed (CRVO) Stock Price, News & Analysis

Company Overview

CervoMed Inc. (NASDAQ: CRVO) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research is centered on therapies that address cognitive and functional impairment associated with disorders of the central nervous system.

CervoMed’s lead product candidate is neflamapimod, an orally administered, small-molecule inhibitor of p38 alpha mitogen-activated protein kinase. The company is evaluating neflamapimod as a potential treatment for dementia with Lewy bodies, a progressive neurodegenerative disorder characterized by cognitive decline, fluctuations in attention, visual hallucinations and movement-related symptoms. The candidate has also been investigated in other conditions involving cognitive impairment.

CervoMed was created through the combination of Diffusion Pharmaceuticals and EIP Pharma, with the combined company adopting the CervoMed name. Its operations are focused on advancing clinical development programs in neurodegenerative disease and working toward potential therapies for patients with limited treatment options.

Key Stats

• Today's Range: $2.67 to $2.92
• 50-Day Range: $2.41 to $3.09
• 52-Week Range: $2.13 to $10.00
• Volume: 448,931 shs
• Average Volume: 1.97 million shs
• Market Capitalization: $43.55 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Moderate Buy

CervoMed Stock Analysis - MarketRank™

CervoMed scored higher than 60% of companies evaluated by MarketBeat, and ranked 354th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CervoMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

CervoMed has a consensus price target of $21.00, representing about 629.7% upside from its current price of $2.88.

Amount of Analyst Coverage

CervoMed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for CervoMed are expected to grow in the coming year, from ($2.38) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of CervoMed is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CervoMed is -0.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CervoMed has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

12.65% of the float of CervoMed has been sold short.

Short Interest Ratio / Days to Cover

CervoMed has a short interest ratio ("days to cover") of 7.15.

Change versus previous month

Short interest in CervoMed has recently decreased by 7.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CervoMed does not currently pay a dividend.

Dividend Growth

CervoMed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.76

News Sentiment

CervoMed has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for CervoMed this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for CRVO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

4 people have added CervoMed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CervoMed insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.80% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

25.15% of the stock of CervoMed is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRVO
• Previous Symbol: NASDAQ:CRVO
• CIK: 1053691
• Web: www.cervomed.com
• Phone: (617) 744-4400
• Fax: 434-220-0722
• Employees: 15
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CervoMed: $21.00
• High Price Target: $31.00
• Low Price Target: $7.00
• Potential Upside/Downside: +629.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.97 million
• Net Margins: -672.80%
• Pretax Margin: -9,141.57%
• Return on Equity: -156.02%
• Return on Assets: -128.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.57
• Quick Ratio: 8.57

Sales & Book Value

• Annual Sales: $4.01 million
• Price / Sales: 10.86
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.97 per share
• Price / Book: 1.46

Miscellaneous

• Outstanding Shares: 15,120,000
• Free Float: 9,706,000
• Market Cap: $43.55 million
• Optionable: Not Optionable
• Beta: -0.64